Finding weaknesses in pancreatic cancer metabolism
Identifying Metabolic Vulnerabilities in Pancreatic Cancer
This study is looking at how pancreatic cancer cells grow and survive in tough conditions, hoping to find weaknesses that could lead to new treatments, and it's designed for people affected by pancreatic cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10903920 on NIH RePORTER |
What this research studies
This research investigates the unique metabolic pathways that pancreatic cancer cells rely on for growth, particularly in challenging environments. Using advanced CRISPR technology, the study aims to identify specific metabolic vulnerabilities that could be targeted for new treatments. By analyzing data from CRISPR screens, researchers will create a detailed map of these dependencies and test potential therapeutic targets in mouse models of pancreatic cancer. This approach seeks to bridge the gap between laboratory findings and real tumor behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer who may benefit from novel therapeutic strategies.
Not a fit: Patients with non-cancerous conditions or those with pancreatic cancer that has already progressed to an advanced stage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatments for pancreatic cancer by targeting its metabolic weaknesses.
How similar studies have performed: Other research has shown promise in targeting metabolic pathways in cancer, suggesting that this approach could yield significant advancements.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Biancur, Douglas — New York University School of Medicine
- Study coordinator: Biancur, Douglas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.